Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Novavax will discontinue negotiations for the previously announced collaboration with Madrid-based ROVI Pharmaceuticals.
Novavax, Inc. (Rockville, MD), will discontinue negotiations for the previously announced collaboration with Madrid-based ROVI Pharmaceuticals to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in Spain. The company had entered into an initial agreement to license its VLP vaccine technology to ROVI in July 2009.
The decision to terminate negotiations was made because of the companies’ inability to agree on acceptable terms of the proposed collaboration and to obtain the necessary funding commitments for the program. Novavax is free to seek a new partner for its pandemic and seasonal influenza vaccine development efforts in Europe in the future.
Meanwhile, Novavax has reported additional positive data from its trivalent seasonal influenza vaccine clinical study that began in May 2009 among healthy adults, 18 to 49 years of age. The data show significant neuraminidase inhibition antibody titers in VLP vaccine recipients. The vaccine also matched the influenza strains recommended for the 2008–2009 influenza season.
Novavax produces its vaccines by using recombinant baculovirus vector and insect cell culture to produce proteins specific to the emerging influenza strain that then self-assemble into an enveloped, non-infectious VLP, similar to that used in Merck’s vaccine against human papillomavirus. The system’s high yields make it possible to produce significant quantities of vaccine using only 1,000–2,000-L disposable bioreactors, which significantly reduces the time and cost of setting up and validating a new production facility.
According to CEO Rahul Singhvi, the company is continuing to make progress with vaccine development in Mexico, India, and the US. In Mexico, Novavax is currently awaiting results from its H1N1 influenza vaccine clinical study. In India, it expects to open a VLP vaccine production facility in March and in the US, the company is awaiting results of its seasonal influenza vaccine study in the elderly.
Previous coverage:
Novavax Licenses VLP Vaccine Technology to Spanish Company ROVI
New Influenza Vaccine Manufacturing Facility in India to Use VLP Technology
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
